Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
17,212
Total Claims
$2.4M
Drug Cost
564
Beneficiaries
$4,317
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-84%
Opioid rate vs peers
0.4% vs 2.2% avg
+206%
Cost per patient vs peers
$4,317 vs $1,411 avg
+92%
Brand preference vs peers
20.4% vs 10.6% avg
Opioid Prescribing
0.4%
Opioid Rate
62
Opioid Claims
$444
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,447 claims · $2.1M
Generic: 13,467 claims · $356K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 397 | $246K |
| Lipase/Protease/Amylase | 145 | $188K |
| Icosapent Ethyl | 356 | $150K |
| Linaclotide | 223 | $137K |
| Empagliflozin | 131 | $96K |
| Lipase/Protease/Amylase | 60 | $91K |
| Denosumab | 52 | $90K |
| Metformin Hcl | 16 | $83K |
| Linagliptin/Metformin Hcl | 112 | $82K |
| Linagliptin | 141 | $79K |
| Dexlansoprazole | 301 | $73K |
| Mirabegron | 122 | $66K |
| Sitagliptin Phos/Metformin Hcl | 86 | $63K |
| Diclofenac Sodium | 23 | $63K |
| Fluticasone/Umeclidin/Vilanter | 81 | $59K |
Prescribing Profile
Patient Profile
77
Avg Age
62%
Female
1.78
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data